Direct answer: The strongest coverage requests connect medical need, safe follow-up, and a clear long-term plan
STEP Clinical Trial Program The landmark STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program represents the most extensive investigation of semaglutide for weight management: STEP 1 (New England Journal of Medicine): Enrolled 1,961 adults with obesity or overweight and demonstrated a mean weight loss of 14.9% from baseline at 68 weeks with semaglutide 2.4 mg compared to 2.4% with placebo
166 Thus, the nasal route to deliver drugs into the brain is rather immature and more high-quality drug delivery systems should note to solve the above-motioned limitations
Cheng KY, Bao Z, Long Y, et al
Paradoxically, this means the very people who benefit most from semaglutide weight loss are also most likely to experience reflux, at least initially